Cargando…
Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologous hematopoietic stem cell transplant (auto-HSCT) r...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827627/ https://www.ncbi.nlm.nih.gov/pubmed/34190658 http://dx.doi.org/10.1080/21645515.2021.1930846 |
_version_ | 1784647674349223936 |
---|---|
author | Dagnew, Alemnew F. Vink, Peter Drame, Mamadou Willer, David O. Salaun, Bruno Schuind, Anne E. |
author_facet | Dagnew, Alemnew F. Vink, Peter Drame, Mamadou Willer, David O. Salaun, Bruno Schuind, Anne E. |
author_sort | Dagnew, Alemnew F. |
collection | PubMed |
description | Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologous hematopoietic stem cell transplant (auto-HSCT) recipients and hematologic malignancy (HM) patients. We review immune responses to RZV in 5 adult IC populations, 4 of which were receiving multiple, concomitant immunosuppressive medications: auto-HSCT and renal transplant recipients, HM and solid tumor patients, and human immunodeficiency virus-infected adults. Although administered in most cases when immunosuppression was near its maximum, including concomitantly with chemotherapy cycles, RZV induced robust and persistent humoral and, more importantly, CMI responses in all 5 IC populations. Based on the overall clinical data generated in older adults and IC individuals, RZV is expected to provide benefit in a broad adult population at risk for HZ. |
format | Online Article Text |
id | pubmed-8827627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-88276272022-02-10 Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview Dagnew, Alemnew F. Vink, Peter Drame, Mamadou Willer, David O. Salaun, Bruno Schuind, Anne E. Hum Vaccin Immunother Mini-Review Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologous hematopoietic stem cell transplant (auto-HSCT) recipients and hematologic malignancy (HM) patients. We review immune responses to RZV in 5 adult IC populations, 4 of which were receiving multiple, concomitant immunosuppressive medications: auto-HSCT and renal transplant recipients, HM and solid tumor patients, and human immunodeficiency virus-infected adults. Although administered in most cases when immunosuppression was near its maximum, including concomitantly with chemotherapy cycles, RZV induced robust and persistent humoral and, more importantly, CMI responses in all 5 IC populations. Based on the overall clinical data generated in older adults and IC individuals, RZV is expected to provide benefit in a broad adult population at risk for HZ. Taylor & Francis 2021-06-30 /pmc/articles/PMC8827627/ /pubmed/34190658 http://dx.doi.org/10.1080/21645515.2021.1930846 Text en © 2021 GlaxoSmithKline Biologicals S.A. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Mini-Review Dagnew, Alemnew F. Vink, Peter Drame, Mamadou Willer, David O. Salaun, Bruno Schuind, Anne E. Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview |
title | Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview |
title_full | Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview |
title_fullStr | Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview |
title_full_unstemmed | Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview |
title_short | Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview |
title_sort | immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview |
topic | Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827627/ https://www.ncbi.nlm.nih.gov/pubmed/34190658 http://dx.doi.org/10.1080/21645515.2021.1930846 |
work_keys_str_mv | AT dagnewalemnewf immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview AT vinkpeter immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview AT dramemamadou immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview AT willerdavido immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview AT salaunbruno immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview AT schuindannee immuneresponsestotheadjuvantedrecombinantzostervaccineinimmunocompromisedadultsacomprehensiveoverview |